Corient Private Wealth LP Acquires New Shares in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Corient Private Wealth LP acquired 139,094 Ultragenyx shares worth approximately $4.64 million, while institutional investors and hedge funds collectively own 97.67% of the company.
• Ultragenyx reported quarterly revenue of $214 million, up 28.5% year over year, and an adjusted loss of $0.90 per share—better than analysts’ expected loss of $1.22.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $59.44 versus a recent share price near $25.21.

Corient Private Wealth LP acquired a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 139,094 shares of the biopharmaceutical company's stock, valued at approximately $4,644,000. Corient Private Wealth LP owned approximately 0.14% of Ultragenyx Pharmaceutical at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $355,746,000. Assenagon Asset Management S.A. increased its holdings in shares of Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company's stock valued at $47,298,000 after acquiring an additional 2,057,951 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company's stock valued at $65,205,000 after acquiring an additional 1,864,164 shares in the last quarter. Norges Bank bought a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $29,004,000. Finally, Bank of America Corp DE acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $38,347,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the sale, the director directly owned 21,095 shares of the company's stock, valued at $528,429.75. This represents a 8.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the firm's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the sale, the executive vice president owned 94,462 shares in the company, valued at $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.20% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Stock Down 1.6%

Shares of NASDAQ:RARE opened at $25.21 on Tuesday. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -4.32 and a beta of 0.35. The business has a 50 day moving average price of $28.47 and a 200 day moving average price of $25.04. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.29 and a twelve month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts' consensus estimates of ($1.22) by $0.32. The company had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company's quarterly revenue was up 28.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.17) earnings per share. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on RARE shares. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Monday, August 10th. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Morgan Stanley boosted their price objective on shares of Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the stock an "overweight" rating in a research note on Friday, August 21st. Guggenheim decreased their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, August 4th. Finally, Royal Bank Of Canada raised their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an "outperform" rating in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $59.44.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source